

Marina Biotech, Inc. to Present at The 13th Annual BIO CEO & Investor Conference
BOTHELL, WA--(Marketwire - February 8, 2011) - Marina Biotech, Inc. (
A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at [ http://www.marinabio.com ]. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at [ http://www.marinabio.com ].